Cancer Nanomedicine
This special issue brings together cutting edge research and insightful commentary on the currentl state of the Cancer Nanomedicine field.
Saved in:
| Sonstige: | |
|---|---|
| Year of Publication: | 2020 |
| Language: | English |
| Physical Description: | 1 electronic resource (510 p.) |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| LEADER | 08661nam-a2203013z--4500 | ||
|---|---|---|---|
| 001 | 993546171904498 | ||
| 005 | 20231214133556.0 | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 202105s2020 xx |||||o ||| 0|eng d | ||
| 035 | |a (CKB)5400000000040899 | ||
| 035 | |a (oapen)https://directory.doabooks.org/handle/20.500.12854/69077 | ||
| 035 | |a (EXLCZ)995400000000040899 | ||
| 041 | 0 | |a eng | |
| 100 | 1 | |a Hoskins, Clare |4 edt | |
| 245 | 1 | 0 | |a Cancer Nanomedicine |
| 260 | |a Basel, Switzerland |b MDPI - Multidisciplinary Digital Publishing Institute |c 2020 | ||
| 300 | |a 1 electronic resource (510 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 520 | |a This special issue brings together cutting edge research and insightful commentary on the currentl state of the Cancer Nanomedicine field. | ||
| 546 | |a English | ||
| 650 | 7 | |a Technology: general issues |2 bicssc | |
| 653 | |a antibody drug conjugate (ADC) | ||
| 653 | |a PD-L1 | ||
| 653 | |a tumor spheroid disruption | ||
| 653 | |a immune modulation | ||
| 653 | |a doxorubicin | ||
| 653 | |a graphene oxide | ||
| 653 | |a adsorption | ||
| 653 | |a cathepsin D | ||
| 653 | |a cathepsin L | ||
| 653 | |a anti-metastatic enzyme cancer therapy | ||
| 653 | |a nanoparticles | ||
| 653 | |a targeted delivery system | ||
| 653 | |a siRNA | ||
| 653 | |a osteopontin | ||
| 653 | |a mammary carcinoma | ||
| 653 | |a mesenchymal stem cells (MSCs) | ||
| 653 | |a TAT peptide | ||
| 653 | |a PLGA | ||
| 653 | |a paclitaxel | ||
| 653 | |a nano-engineered MSCs | ||
| 653 | |a orthotopic lung tumor model | ||
| 653 | |a intracranial glioma | ||
| 653 | |a immunotherapy | ||
| 653 | |a CPMV | ||
| 653 | |a viral nanoparticles | ||
| 653 | |a in situ vaccine | ||
| 653 | |a albumin nanoparticles | ||
| 653 | |a microbubble | ||
| 653 | |a ultrasound | ||
| 653 | |a theranostics | ||
| 653 | |a hepatocellular carcinoma | ||
| 653 | |a VX2 tumor | ||
| 653 | |a intra-arterial chemotherapy | ||
| 653 | |a lung cancer | ||
| 653 | |a nanomedicine | ||
| 653 | |a clinical status | ||
| 653 | |a cancer therapy | ||
| 653 | |a breast cancer | ||
| 653 | |a cell signaling | ||
| 653 | |a active targeting | ||
| 653 | |a passive targeting | ||
| 653 | |a EPR effect | ||
| 653 | |a oncogenes | ||
| 653 | |a nanoparticle | ||
| 653 | |a drug delivery | ||
| 653 | |a ligand | ||
| 653 | |a tumor targeting | ||
| 653 | |a biodistribution | ||
| 653 | |a Mesoporous silica nanoparticle | ||
| 653 | |a drug delivery system | ||
| 653 | |a target treatment | ||
| 653 | |a lanthanide metal | ||
| 653 | |a hyaluronic acid | ||
| 653 | |a hyaluronidase | ||
| 653 | |a drug combination | ||
| 653 | |a everolimus | ||
| 653 | |a dual-targeting | ||
| 653 | |a magnetic nanoparticles | ||
| 653 | |a monoclonal antibodies | ||
| 653 | |a nanostructured lipid carrier | ||
| 653 | |a platelet membrane | ||
| 653 | |a biomimicry | ||
| 653 | |a plasmonic photothermal therapy | ||
| 653 | |a gold nanorods | ||
| 653 | |a surgery | ||
| 653 | |a bleeding | ||
| 653 | |a dogs | ||
| 653 | |a cats | ||
| 653 | |a stimuli-responsive | ||
| 653 | |a DOX | ||
| 653 | |a SN38 | ||
| 653 | |a CSCs | ||
| 653 | |a single-walled carbon nanotubes | ||
| 653 | |a chirality separation | ||
| 653 | |a NASH | ||
| 653 | |a drug-gene delivery | ||
| 653 | |a near IR hyperspectral imaging | ||
| 653 | |a plasmonics | ||
| 653 | |a copper | ||
| 653 | |a VEGF | ||
| 653 | |a glioblastoma | ||
| 653 | |a differentiated neuroblastoma | ||
| 653 | |a peptidomimetics | ||
| 653 | |a real-time quantitative polymerase chain reaction (qPCR) | ||
| 653 | |a actin | ||
| 653 | |a combinatorial therapy | ||
| 653 | |a anticancer and antibacterial activity | ||
| 653 | |a temoporfin | ||
| 653 | |a drug-in-cyclodextrin-in-liposome | ||
| 653 | |a hybrid nanoparticles | ||
| 653 | |a multicellular tumor spheroids | ||
| 653 | |a cyclodextrins | ||
| 653 | |a photodynamic therapy article | ||
| 653 | |a yet reasonably common within the subject discipline | ||
| 653 | |a antitumor strategy | ||
| 653 | |a biomimetic core–shell nanoparticles | ||
| 653 | |a NK cell-derived exosomes | ||
| 653 | |a folate receptor | ||
| 653 | |a albumin nanoparticle | ||
| 653 | |a microfluidic | ||
| 653 | |a cabazitaxel | ||
| 653 | |a polydopamine nanoparticles | ||
| 653 | |a size | ||
| 653 | |a cytotoxicity | ||
| 653 | |a iron affinity | ||
| 653 | |a FA-DABA-SMA | ||
| 653 | |a self-assembly | ||
| 653 | |a oncogenic proteins | ||
| 653 | |a intracellular disruption | ||
| 653 | |a folic receptor alpha | ||
| 653 | |a pancreatic cancer | ||
| 653 | |a parvifloron D | ||
| 653 | |a albumin | ||
| 653 | |a erlotinib | ||
| 653 | |a photodynamic therapy | ||
| 653 | |a lipid nanoparticles | ||
| 653 | |a tumor vectorization | ||
| 653 | |a verteporfin | ||
| 653 | |a ovarian carcinomatosis | ||
| 653 | |a spheroids | ||
| 653 | |a integrin | ||
| 653 | |a RGD peptide | ||
| 653 | |a cancer diagnosis | ||
| 653 | |a radiotherapy | ||
| 653 | |a hyperthermia therapy | ||
| 653 | |a biomimetic | ||
| 653 | |a nanocarrier | ||
| 653 | |a membrane-wrapped | ||
| 653 | |a cancer | ||
| 653 | |a targeted delivery | ||
| 653 | |a photothermal therapy | ||
| 653 | |a imaging | ||
| 653 | |a cancer nanomedicine | ||
| 653 | |a tumor microenvironment | ||
| 653 | |a nano–bio interactions | ||
| 653 | |a clinical translation | ||
| 653 | |a magnetic nanowires | ||
| 653 | |a magnetic hyperthermia | ||
| 653 | |a magnetic actuation | ||
| 653 | |a magnetic drug targeting | ||
| 653 | |a titanate nanotubes | ||
| 653 | |a gold nanoparticles | ||
| 653 | |a vectorization | ||
| 653 | |a colloidal stability | ||
| 653 | |a docetaxel | ||
| 653 | |a prostate cancer | ||
| 653 | |a mangiferin | ||
| 653 | |a anti-topoisomerase activity | ||
| 653 | |a extracellular vesicles | ||
| 653 | |a exosomes | ||
| 653 | |a chemico-physical functionalization | ||
| 653 | |a loading | ||
| 653 | |a translational medicine | ||
| 653 | |a nanotechnology: bioengineering | ||
| 653 | |a anacardic acid | ||
| 653 | |a mitoxantrone | ||
| 653 | |a targeted drug delivery | ||
| 653 | |a liposomes | ||
| 653 | |a melanoma | ||
| 653 | |a apoptosis | ||
| 653 | |a ascorbic acid | ||
| 653 | |a angiogenesis | ||
| 653 | |a epithelial-to-mesenchymal transition | ||
| 653 | |a hypoxia | ||
| 653 | |a immunosuppression | ||
| 653 | |a metabolism | ||
| 653 | |a nanotherapeutics | ||
| 653 | |a tumour microenvironment | ||
| 653 | |a DNA origami | ||
| 653 | |a liposome | ||
| 653 | |a remote loading | ||
| 653 | |a acute toxicity | ||
| 653 | |a organoids | ||
| 653 | |a magnetic silica-coated iron oxide nanochains | ||
| 653 | |a photothermal treatment | ||
| 653 | |a hyperthermia | ||
| 653 | |a collagen | ||
| 653 | |a cellular microenvironment | ||
| 653 | |a lymphadenectomy | ||
| 653 | |a magnetometer | ||
| 653 | |a sentinel lymph node dissection | ||
| 653 | |a SPION | ||
| 653 | |a superparamagnetic iron oxide nanoparticles | ||
| 653 | |a Vδ2 T cells | ||
| 653 | |a zoledronic acid | ||
| 653 | |a polymeric nanoconstruct | ||
| 653 | |a anti-tumor immunity | ||
| 653 | |a colorectal carcinoma | ||
| 653 | |a β-cyclodextrin nanosponges | ||
| 653 | |a BALB-neuT mice | ||
| 653 | |a brain tumours | ||
| 653 | |a glioma | ||
| 653 | |a blood brain barrier | ||
| 653 | |a polymeric nanoparticles | ||
| 653 | |a PEGylation | ||
| 653 | |a dioleoylphosphatidylethanolamine | ||
| 653 | |a poly(hydroxyethyl acrylate-co-allyl methyl sulfide) copolymer | ||
| 653 | |a folate | ||
| 653 | |a oxidation-sensitive release | ||
| 653 | |a cellular interaction | ||
| 653 | |a in vitro anti-cancer activity | ||
| 653 | |a triple negative breast cancer | ||
| 653 | |a organotin | ||
| 653 | |a mesoporous silica nanoparticles | ||
| 653 | |a MDA-MB-231 | ||
| 653 | |a theranostic nanomaterials | ||
| 653 | |a nanobiotechnology | ||
| 653 | |a molecular imaging | ||
| 653 | |a nanosystems | ||
| 653 | |a nanomicelles | ||
| 653 | |a ovarian cancer | ||
| 653 | |a tumour targeting | ||
| 653 | |a chemotherapeutics | ||
| 653 | |a riboflavin | ||
| 653 | |a vitamin B2 | ||
| 653 | |a nanomedicines | ||
| 653 | |a secondary structure | ||
| 653 | |a mixed micelle | ||
| 653 | |a pH responsive | ||
| 653 | |a targeted therapy | ||
| 653 | |a anti-cancer | ||
| 653 | |a shear stress | ||
| 653 | |a flow | ||
| 653 | |a in vitro | ||
| 653 | |a therapeutics | ||
| 653 | |a diagnostics | ||
| 653 | |a Immunotherapy | ||
| 776 | |z 3-03943-058-0 | ||
| 776 | |z 3-03943-059-9 | ||
| 700 | 1 | |a Hoskins, Clare |4 oth | |
| 906 | |a BOOK | ||
| ADM | |b 2023-12-15 05:58:13 Europe/Vienna |f system |c marc21 |a 2022-04-04 09:22:53 Europe/Vienna |g false | ||
| AVE | |i DOAB Directory of Open Access Books |P DOAB Directory of Open Access Books |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338154150004498&Force_direct=true |Z 5338154150004498 |b Available |8 5338154150004498 | ||